Biogen agreed to acquire Apellis Pharmaceuticals for about $5.6 billion, extending the company’s immunology and rare-disease footprint. The deal brings two marketed therapies—Empaveli and Syfovre—alongside Apellis’ nephrology and immune-directed expertise as Biogen prepares additional launches, including felzartamab.